R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study-Reference-Cited by-同舟云学术

R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study

Published:2020-03-31 Issue:7 Volume:38 Page:765-776
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Hart Rose^ORCID,Burns Darren^ORCID,Ramaekers Bram^ORCID,Ren Shijie^ORCID,Gladwell Daniel,Sullivan Will^ORCID,Davison Niall^ORCID,Saunders Owain,Sly Indeg,Cain Theresa,Lee Dawn

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-020-00903-9.pdf

Reference64 articles.

1. Microsoft R Application Network. Introduction to R. 2019. https://mran.microsoft.com/documents/what-is-r. Accessed 6 Feb 2019.

2. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. https://www.R-project.org/. Accessed 10 May 2019.

3. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1–233.

4. National Institute for Health and Care Excellence (NICE). Rituximab for the first-line treatment of stage III–IV follicular lymphoma (TA243). 2012. https://www.nice.org.uk/guidance/ta243. Accessed 11 June 2019.

5. Institute for Clinical and Economic Review (ICER). Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value. 2018. https://icer-review.org/wp-content/uploads/2018/04/ICER_OUD_Final_Evidence_Report_120318.pdf. Accessed 11 June 2019.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China;BMJ Open;2024-08

2. NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances;PharmacoEconomics - Open;2024-04-13

3. Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results;PharmacoEconomics;2024-04-12

4. Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysis;HEALTH TECHNOL ASSES;2024

5. #SharingHEOR: Developing Modern Media for Communication and Dissemination of Health Economics and Outcomes Research;Applied Health Economics and Health Policy;2024-03-01